Jianhui Li , Jiong Li

1 Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800, Zhejiang, China
2 Biotechnology Research Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 2   
Received: 12 Apr., 2024    Accepted: 16 May, 2024    Published: 28 May, 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study explores the application of CRISPR-Cas9 gene editing technology in organ transplantation, particularly its potential in reducing immunogenicity and enhancing the longevity of pig organs. The research focuses on strategies to reduce immune rejection through gene editing, specifically targeting genes such as GGTA1, CMAH, and β4GalNT2. Experimental results demonstrate that these genetic modifications significantly reduce the immunogenicity of pig organs. The study also investigates mechanisms to improve organ tolerance and function through gene editing, such as upregulation of anti-apoptotic and antioxidant genes, and strategies to mitigate ischemia-reperfusion injury. The article concludes with an assessment of the potential breakthroughs and future prospects of CRISPR-Cas9 in xenotransplantation, emphasizing the technical challenges and ethical considerations that need to be addressed in future research and clinical applications.

CRISPR-Cas9; Gene editing; Immunogenicity; Xenotransplantation